| Autor: |
Lansangan C; Division of Cancer Science, Departments of Basic Sciences and Neurosurgery, School of Medicine, Loma Linda University (LLU), 11175 Campus St., Loma Linda, CA 92350, USA., Khoobchandani M; Division of Cancer Science, Departments of Basic Sciences and Neurosurgery, School of Medicine, Loma Linda University (LLU), 11175 Campus St., Loma Linda, CA 92350, USA., Jain R; Department of Surgery, Government Medical College, Miraj 416410, India., Rudensky S; Division of Cancer Science, Departments of Basic Sciences and Neurosurgery, School of Medicine, Loma Linda University (LLU), 11175 Campus St., Loma Linda, CA 92350, USA., Perry CC; Division of Biochemistry, Department of Basic Sciences, School of Medicine, Loma Linda University (LLU), 11175 Campus St., Loma Linda, CA 92350, USA., Patil R; Division of Cancer Science, Departments of Basic Sciences and Neurosurgery, School of Medicine, Loma Linda University (LLU), 11175 Campus St., Loma Linda, CA 92350, USA. |
| Abstrakt: |
Glioblastoma multiforme (GBM) is a glioma and the most aggressive type of brain tumor with a dismal average survival time, despite the standard of care. One promising alternative therapy is boron neutron capture therapy (BNCT), which is a noninvasive therapy for treating locally invasive malignant tumors, such as glioma. BNCT involves boron-10 isotope capturing neutrons to form boron-11, which then releases radiation directly into tumor cells with minimal damage to healthy tissues. This therapy lacks clinically approved targeted blood-brain-barrier-permeating delivery vehicles for the central nervous system (CNS) entry of therapeutic boron-10. Gold nanoparticles (GNPs) are selective and effective drug-delivery vehicles because of their desirable properties, facile synthesis, and biocompatibility. This review discusses biomedical/therapeutic applications of GNPs as a drug delivery vehicle, with an emphasis on their potential for carrying therapeutic drugs, imaging agents, and GBM-targeting antibodies/peptides for treating glioma. The constraints of GNP therapeutic efficacy and biosafety are discussed. |
